Evidence map›Paper›PMID 42425763›Full record

ArticleLife science alliance2026

Vav2 is a master regulator of repair against bacterial pore-forming toxins.

Victor Gbenga Kayejo, Ashlee Hensley, Tejal Katore, Peter A Keyel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Victor Gbenga KayejoDepartment of Biological Sciences, Texas Tech University, Lubbock, TX, USA.
Ashlee HensleyDepartment of Biological Sciences, Texas Tech University, Lubbock, TX, USA.
Tejal KatoreDepartment of Biological Sciences, Texas Tech University, Lubbock, TX, USA.
Peter A KeyelDepartment of Biological Sciences, Texas Tech University, Lubbock, TX, USA peter.keyel@ttu.edu.ORCID https://orcid.org/0000-0001-8637-8538

Funding

Novel membrane defense systems utilized by the human pathogen LeishmaniaR21AI156225 · NIAID · TEXAS TECH UNIVERSITY · PI KEYEL, PETER A · 2021 to 2022
$405k
American Heart Association-American Stroke Association 23IPA1053083NIAID NIH HHS R21 AI156225
6 · The paper itself

Abstract

Despite antibiotic therapy, 25-35% of patients with necrotizing soft tissue infections (NSTIs) die. The etiologic agents for NSTIs include

Indexed as

Bacterial ToxinsProto-Oncogene Proteins c-vavAnimalsBacterial ProteinsCalciumCell MembraneClostridium perfringensHemolysin ProteinsHumansSignal TransductionStreptococcus pyogenesStreptolysinsBacterial ProteinsBacterial ToxinsCalciumHemolysin ProteinsProto-Oncogene Proteins c-vavstreptolysin OStreptolysinsVAV2 protein, human

Identifiers

PMID42425763
PMCPMC13351264

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.